ADRB2 and cancer: The ability of propranolol to switch macrophages into an M2-like phenotype and to increase the anti-inflammatory clearance activity of macrophages might be a key mechanism to explain, in part, the increased survival associated with β-AR blocker-based therapies for patients with cancer [53,54], previous myocardial infarction and atherosclerosis [55,56].